Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity.
Mostafa Wanees Ahmed El HussenyMediana MamdouhSara ShabanAbdelrahman Ibrahim AbushoukMarwa Mostafa Mohamed ZakiOsama M AhmedMohamed M Abdel-DaimPublished in: Journal of diabetes research (2017)
Adipokines are bioactive molecules that regulate several physiological functions such as energy balance, insulin sensitization, appetite regulation, inflammatory response, and vascular homeostasis. They include proinflammatory cytokines such as adipocyte fatty acid binding protein (A-FABP) and anti-inflammatory cytokines such as adiponectin, as well as vasodilator and vasoconstrictor molecules. In obesity and type II diabetes mellitus (DM), insulin resistance causes impairment of the endocrine function of the perivascular adipose tissue, an imbalance in the secretion of vasoconstrictor and vasodilator molecules, and an increased production of reactive oxygen species. Recent studies have shown that targeting plasma levels of adipokines or the expression of their receptors can increase insulin sensitivity, improve vascular function, and reduce the risk of cardiovascular morbidity and mortality. Several reviews have discussed the potential of adipokines as therapeutic targets for type II DM and obesity; however, this review is the first to focus on their therapeutic potential for vascular dysfunction in type II DM and obesity.
Keyphrases
- insulin resistance
- adipose tissue
- glycemic control
- metabolic syndrome
- high fat diet induced
- type diabetes
- high fat diet
- binding protein
- weight loss
- skeletal muscle
- polycystic ovary syndrome
- inflammatory response
- reactive oxygen species
- fatty acid
- weight gain
- oxidative stress
- poor prognosis
- randomized controlled trial
- cancer therapy
- physical activity
- toll like receptor
- human health
- systematic review